A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Clinical trial NCT00948961 · COMPLETED

Trial details

NCT number: NCT00948961
Sponsor: Celldex Therapeutics
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Malignancies

Start date: 2009-09-01
Primary completion: 2012-06-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.